NAFLD/NASH: Strategies for Accelerating Drug Discovery with an Improved Metabolic Dysregulation Model
Presenter: Dr. Judith Gorski, Crown Bioscience Inc.
Metabolic disturbances such as insulin resistance, obesity, and dyslipidemia are prominent risk factors in the development of non-alcoholic fatty liver disease (NAFLD), which can progress to the more severe non-alcoholic steatohepatitis (NASH). With no treatments currently approved for NAFLD/NASH, preclinical models are needed for novel drug assessment which fully recapitulate the backgrounds and phenotypes seen in human disease.
This webinar discusses strategies for incorporating a new model into preclinical studies that develops metabolic dysregulation - obesity, hyperglycemia, insulin resistance, and dyslipidemia, within an intact leptin signaling background. The model further develops NAFLD and NASH when fed a western diet supplemented with fructose, improving the translation into humans and accelerating discovery of new treatments.
Watch this webinar to learn how:
- The MS-NASH (formerly called FATZO) mouse represents a new model for the study of progressive NAFLD and NASH with concurrent metabolic dysregulation
- To optimize preclinical NAFLD/NASH study design for efficacy
- Potential therapeutics are used to prevent histological evidence of hepatic steatosis, lobular inflammation, ballooning, and fibrosis in this model
About The Presenter:
Dr. Judith Gorski is Global Director of Scientific Engagement at Crown Bioscience Inc., and is a pharmacologist with over 18 years of experience in drug discovery and development in a large pharmaceutical environment. She has extensive experience in basic research and targeted drug discovery in the disease areas of type 1 and 2 diabetes, dyslipidemia, atherosclerosis, obesity, and metabolic syndrome. Dr. Gorski has co-authored publications in Nature, Obesity, Obesity Research, Cell Metabolism, Journal of Lipid Metabolism.
Prior to joining CrownBio, Dr. Gorski's work at Merck focused on target identification/validation and small molecule and biologics identification/optimization with the aim of recommending lead candidates for clinical development. She is an expert at establishing and validating primary, secondary and tertiary in vivo models of dyslipidemia, obesity, metabolic syndrome, and type 1 and 2 diabetes.
Dr. Gorski received her Ph.D. in Neuroscience from University of Medicine and Dentistry, New Jersey.